Viracta Therapeutics, Inc.
DelistedCIK 1061027fmd_0X254TXMPXAEQ7X73468XJC2K0Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2024, 59 periods
Latest annual · FY2020
Millions- Total revenues
- 0
- Operating income
- (51)
- Net income
- (51)
- Free cash flow
- (40)
Latest quarter · Q3 FY2024
Millions- Operating income
- (10)
- Net income
- (11)
- Free cash flow
- (7)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2018 to FY2023
- n/m
Viracta Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Operating income | -$50.7 million | -$50.6 million | 10-K 2024-03-07 · proof | |
| Net income | -$51.1 million | -$49.2 million | 10-K 2024-03-07 · proof | |
| Cash from operating activities | -$39.9 million | -$35.5 million | 10-K 2024-03-07 · proof | |
| Free cash flow | -$40 million | -$35.5 million | 10-K 2024-03-07 · proof | |
| Total assets | $56.7 million | $96 million | -40.9% | 10-K 2024-03-07 · proof |
| Total liabilities | $38.4 million | $34.9 million | +10% | 10-K 2024-03-07 · proof |
| Cash and cash equivalents | $12.3 million | $36.8 million | -66.5% | 10-K 2024-03-07 · proof |
| Total debt | $25.3 million | 10-K 2024-03-07 · proof |
- What was Viracta Therapeutics, Inc.'s operating income in fiscal 2023?
- Viracta Therapeutics, Inc. reported operating income of -$50.7 million for fiscal 2023 (the year ended Dec 31, 2023), against -$50.6 million the year before. Source: the 10-K filed with the SEC on Mar 7, 2024. SEC
- What was Viracta Therapeutics, Inc.'s net income in fiscal 2023?
- Viracta Therapeutics, Inc. reported net income of -$51.1 million for fiscal 2023 (the year ended Dec 31, 2023), against -$49.2 million the year before. Source: the 10-K filed with the SEC on Mar 7, 2024. SEC
- What was Viracta Therapeutics, Inc.'s cash from operating activities in fiscal 2023?
- Viracta Therapeutics, Inc. reported cash from operating activities of -$39.9 million for fiscal 2023 (the year ended Dec 31, 2023), against -$35.5 million the year before. Source: the 10-K filed with the SEC on Mar 7, 2024. SEC
- What was Viracta Therapeutics, Inc.'s free cash flow in fiscal 2023?
- Viracta Therapeutics, Inc. reported free cash flow of -$40 million for fiscal 2023 (the year ended Dec 31, 2023), against -$35.5 million the year before. Source: the 10-K filed with the SEC on Mar 7, 2024. SEC
- What are Viracta Therapeutics, Inc.'s total assets?
- As of Dec 31, 2023, Viracta Therapeutics, Inc. reported total assets of $56.7 million, against $96 million a year earlier (-40.9%). Source: the 10-K filed with the SEC on Mar 7, 2024. SEC
- What are Viracta Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2023, Viracta Therapeutics, Inc. reported total liabilities of $38.4 million, against $34.9 million a year earlier (+10%). Source: the 10-K filed with the SEC on Mar 7, 2024. SEC
- What are Viracta Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2023, Viracta Therapeutics, Inc. reported cash and cash equivalents of $12.3 million, against $36.8 million a year earlier (-66.5%). Source: the 10-K filed with the SEC on Mar 7, 2024. SEC
- What is Viracta Therapeutics, Inc.'s total debt?
- As of Dec 31, 2023, Viracta Therapeutics, Inc. reported total debt of $25.3 million. Source: the 10-K filed with the SEC on Mar 7, 2024. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1061027&period_type=annual&limit=5"Information only, not investment advice.